Loading…
Estrella Immunopharma, Inc. is projected to decline to $0.6687 by 2027, a -4% move from its current price of $0.70. ESLA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.6719 | $0.6994 | $0.7281 | -0.08% |
| Aug 6 | $0.6602 | $0.6988 | $0.7396 | -0.17% |
| Aug 7 | $0.6513 | $0.6982 | $0.7485 | -0.25% |
| Aug 8 | $0.6438 | $0.6976 | $0.756 | -0.34% |
| Aug 9 | $0.6372 | $0.6971 | $0.7625 | -0.42% |
| Aug 10 | $0.6312 | $0.6965 | $0.7684 | -0.51% |
| Aug 11 | $0.6257 | $0.6959 | $0.7739 | -0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6257 | $0.6959 | $0.7739 | -0.59% |
| Week 2 | $0.5953 | $0.6918 | $0.8039 | -1.18% |
| Week 3 | $0.5721 | $0.6877 | $0.8266 | -1.76% |
| Week 4 | $0.5528 | $0.6836 | $0.8455 | -2.34% |
| Week 5 | $0.5359 | $0.6796 | $0.8618 | -2.91% |
| Week 6 | $0.5208 | $0.6756 | $0.8764 | -3.49% |
| Week 7 | $0.5071 | $0.6716 | $0.8896 | -4.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company that develops T-cell therapies for blood cancers and solid tumors in the United States. Its lead product EB103 is in Phase I/II for the treatment of diffuse large B-cell lymphoma, with EB104 in pre-clinical trial for diffuse large B-cell lymphoma and acute lymphocytic leukemia, and EB201 in pre-clinical trial for systemic lupus erythematosus.
The company offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for hematologic malignancies, and has a collaborative agreement with Eureka and Imugene Limited for solid tumor treatments using Imugene's CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. It is a subsidiary of Eureka Therapeutics, Inc.
The ESLA stock is currently priced at $0.761, with a market cap of $32.75M and a market ranking of 4540. The technical backdrop shows bearish momentum, with a current RSI of 30 and key moving averages positioned above the current price, signaling limited near‑term upside.
In the near term, the stock trades within a 30-day range of $0.568 to $1.02, with a support level at $0.742 and a resistance at $1.15, underscoring a cautious outlook while volatility remains elevated (annualized volatility 80%).
A major floor 29.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.0% away) — a key level to hold.
The nearest ceiling, 48.6% above — a clean break opens room to run.
A major ceiling 174.3% above — clearing it would confirm fresh momentum.
Key ESLA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ESLA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7474 | Sell | $0.7417 | Sell |
| MA 10 | $0.7667 | Sell | $0.7668 | Sell |
| MA 20 | $0.821 | Sell | $0.8189 | Sell |
| MA 50 | $0.9653 | Sell | $0.9564 | Sell |
| MA 100 | $1.17 | Sell | $1.09 | Sell |
| MA 200 | $1.39 | Sell | $1.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.55 | Neutral |
| Stoch RSI (14) | 46.88 | Neutral |
| CCI (20) | -104.90 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -7.51 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.10 | Sell |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 34.09 | Neutral |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 0.73 | Sell |
| ADX (14) | 27.11 | Sell |
| ATR (14) | 0.03 | Info |
The near-term technical picture is bearish, with RSI14 at 30 indicating modest momentum to the downside. The stock trades below its 50-day and 200-day moving averages, with SMA50 at $1.02 and SMA200 at $1.41.
A defined support is seen at $0.742 and a resistance at $1.15, while the 30-day range has a low of $0.568 and a high of $1.02. These levels suggest limited upside pressure in the immediate horizon unless buyers push through the near-term resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.70 | $0.70 | $0.8891 | 0% | Neutral | |
| $0.5107 | $0.6687 | $0.9381 | -4% | Neutral | |
| $0.513 | $0.7018 | $1.04 | 0% | Neutral | |
| $0.4596 | $0.6522 | $1.00 | -7% | Neutral | |
| $0.5367 | $0.7869 | $1.25 | +12% | Neutral | |
| $0.651 | $0.9837 | $1.61 | +41% | Bullish | |
| $0.6472 | $1.01 | $1.69 | +44% | Bullish | |
| $0.6153 | $0.9825 | $1.69 | +40% | Bullish | |
| $0.5699 | $0.9337 | $1.64 | +33% | Bullish | |
| $0.5814 | $0.9765 | $1.75 | +40% | Bullish | |
| $0.7605 | $1.43 | $2.78 | +105% | Bullish | |
| $0.9688 | $2.15 | $4.67 | +208% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.70 | $0.70 | $0.8592 | +0.00% |
| September 2026 | $0.5608 | $0.6721 | $0.8343 | -3.98% |
| October 2026 | $0.5353 | $0.6481 | $0.8172 | -3.58% |
| November 2026 | $0.552 | $0.674 | $0.8605 | +4.00% |
| December 2026 | $0.5597 | $0.6887 | $0.8891 | +2.18% |
Click any year to see its month-by-month ESLA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ESLA is projected to trade between $0.70 and $0.8891, averaging $0.70 — a potential gain of 0% from today's $0.70. Price action looks broadly range-bound.
Estrella Immunopharma, Inc.'s 2027 outlook centres on $0.6687, within a $0.5107 to $0.9381 range. That is -4% versus the projected 2026 average. That marks a -4% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, ESLA could reach as high as $1.04, with a base case around $0.7018 and support toward $0.513 — roughly 0% from $0.70. Price action looks broadly range-bound.
Expect ESLA to range from $0.4596 to $1.00 through 2029. The $0.6522 average target implies a -7% move from current prices. That is -7% versus the projected 2028 average. A consolidation phase looks the most probable path here.
The ESLA price prediction for 2030 points to an average of $0.7869 (low $0.5367, high $1.25) — a potential gain of +12% on today's $0.70. Price action looks broadly range-bound.
In 2031, ESLA is projected to trade between $0.651 and $1.61, averaging $0.9837 — a potential gain of +41% from today's $0.70. That is up +25% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Estrella Immunopharma, Inc.'s 2032 outlook centres on $1.01, within a $0.6472 to $1.69 range. That is up +2% on the projected 2031 average. That marks a +44% change versus current levels. Momentum favours further upside here.
By 2033, ESLA could reach as high as $1.69, with a base case around $0.9825 and support toward $0.6153 — roughly +40% from $0.70. Buyers look set to stay in control over this stretch.
Expect ESLA to range from $0.5699 to $1.64 through 2034. The $0.9337 average target implies a +33% move from current prices. That is -5% versus the projected 2033 average. Momentum favours further upside here.
The ESLA price prediction for 2035 points to an average of $0.9765 (low $0.5814, high $1.75) — a potential gain of +40% on today's $0.70. Buyers look set to stay in control over this stretch.
In 2040, ESLA is projected to trade between $0.7605 and $2.78, averaging $1.43 — a potential gain of +105% from today's $0.70. That is up +47% on the projected 2035 average. Momentum favours further upside here.
Estrella Immunopharma, Inc.'s 2050 outlook centres on $2.15, within a $0.9688 to $4.67 range. That is up +50% on the projected 2040 average. That marks a +208% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ESLA today (≈ 1,428.571429 ESLA) could be worth
$3,075.48
+$2,075.48 (+208%) by 2050 · US Dollar
Based on the average projected ESLA price of $2.15 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ESLAwould be worth at today's price.
$1,000 invested in ESLA on Jul 31, 2025 (≈ 1,190.476228 ESLA) would be worth
$833.33
-$166.67 (-16.7%) today · 0.83× · US Dollar
Based on a ESLA entry price of $0.84 vs. today's $0.7.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.78 | $897.44 | -10.3% |
| 1 month ago | $0.983 | $712.11 | -28.8% |
| 3 months ago | $1.63 | $429.45 | -57.1% |
| 6 months ago | $1.09 | $642.2 | -35.8% |
| 1 year ago | $0.84 | $833.33 | -16.7% |
| All time (4.9y) ago | $9.75 | $71.79 | -92.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ESLA forecast.
Our base-case forecast reaches $1.40 around 2040.
Implied market cap at $1.40: $60.25M
The multi-year forecast shows a path from flat to modest gains in the near term toward a more bullish trajectory later in the decade. In 2026 the avg price is $0.761 with a min of $0.742 and a max of $0.969, and an ROI of 0%; sentiment is NEUTRAL. The outlook improves into 2031, where the avg reaches $1.10 with an ROI of 44.5% and a BULLISH stance, followed by 2032 (avg $1.07, ROI 40%), 2033 (avg $1.05, ROI 38.5%), 2034 (avg $1.02, ROI 34.4%), and 2035 (avg $1.02, ROI 33.5%), all labeled BULLISH.
By 2040 the avg increases to $1.55 with an ROI of 103.7%, and by 2050 the avg is $2.25 with an ROI of 196.3%, continuing a BULLISH outlook. These yearly figures illustrate a potential long-run upside despite early-year volatility and recurring negative episodes in some years.
Tap a question to reveal the answer.
Avg price is $0.8506, with a min of $0.5627, a max of $1.39, and ROI of 11.8%; sentiment NEUTRAL.
The forecast shows mixed results: 2026 starts at avg $0.761 with ROI 0%, while some years (e.g., 2027 ROI -5.9%, 2029 ROI -11.6%) are negative, and later years show meaningful upside (2031 ROI 44.5%, 2050 ROI 196.3%). This indicates high risk and potential for substantial gains, not a guaranteed outcome.
Yes. The forecast includes years with avg prices above $1.00, such as 2031 (avg $1.10), 2032 (avg $1.07), 2033 (avg $1.05), 2034 (avg $1.02), and 2035 (avg $1.02).
Current price: $0.761. Market cap: $32.75M.
The near-term setup is bearish with RSI14 at 30. The price is supported at $0.742 and faces resistance at $1.15, within a 30-day range of $0.568 to $1.02 and with SMA50 at $1.02 and SMA200 at $1.41.
Estrella Immunopharma, Inc. Community Discussion
0Share your Estrella Immunopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.